Unresolved questions regarding the promise of the TPEx regimen – Authors' reply
Volume: 22, Issue: 6, Pages: e228 - e229
Published: Jun 1, 2021
Abstract
We thank Makoto Kosaka and colleagues for their insightful comments on the report of our TPExtreme (TPEx) regimen in recurrent and metastatic head and neck cancer. 1 Guigay J Aupérin A Fayette J et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label,...
Paper Details
Title
Unresolved questions regarding the promise of the TPEx regimen – Authors' reply
Published Date
Jun 1, 2021
Volume
22
Issue
6
Pages
e228 - e229
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History